Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

Home/Biomarker

MET exon 14 skipping

Gene: MET · Type: mutation

Indications: Non-small cell lung cancer

Sensitivity Resistance CIViC Context

Linked CIViC Profile: MET EXON 14 SKIPPING MUTATION

Evidence Level Distribution

Level A: 1Level B: 2Level C: 7Level D: 2

Level	Type	Direction	Significance	Disease	Drugs	Rating
A	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Capmatinib	4
D	Predictive	Supports	Sensitivity/Response	Cancer	Crizotinib	3
C	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Crizotinib	3
C	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Crizotinib	3
C	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Capmatinib	3
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Tepotinib	3
C	Predictive	Supports	Sensitivity/Response	Histiocytic And Dendritic Cell Cancer	Crizotinib	3
D	Predictive	Supports	Sensitivity/Response	Cancer	Capmatinib	3
C	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Crizotinib	2
C	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	2
C	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Crizotinib	1
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	1